Phase II study of a PARP inhibitor, talazoparib, in HER2-metastatic breast cancer with a somatic BRCA1/2 mutation present in cell-free DNA or tumor tissue genotyping

被引：0
|
作者：
Vidula, Neelima
Damodaran, Senthil
Bhave, Manali
Rugo, Hope
Shah, Ami N.
Blouch, Erica
Ruffle-Deignan, Nathan Royce
Ogbenna, Ogadinma
Flaum, Lisa E.
Cristofanilli, Massimo
Sparano, Joseph
Ostrer, Harry
Abramson, Vandana
Horick, Nora
Bardia, Aditya
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-19-06
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-19-06
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.
    Telli, Melinda L.
    Litton, Jennifer Keating
    Beck, Joseph Thaddeus
    Jones, Jason M.
    Andersen, Jay
    Mina, Lida A.
    Brig, Raymond
    Danso, Michael A.
    Yuan, Yuan
    Symmans, William Fraser
    Abbattista, Antonello
    Noonan, Kay
    Mata, Marielena
    Laird, Douglas
    Blum, Joanne Lorraine
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [42] A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study
    Dey, Shatovisha
    Marino, Natascia
    Bishop, Kanokwan
    Dahlgren, Paige N.
    Shendre, Aditi
    Storniolo, Anna Maria
    He, Chunyan
    Tanaka, Hiromi
    ONCOTARGET, 2018, 9 (03) : 4214 - 4222
  • [43] Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket study
    Boni, V
    Pistilli, B.
    Brana, I
    Shapiro, G., I
    Trigo, J.
    Moreno, V
    Castellano, D.
    Fernandez, C.
    Kahatt, C.
    Alfaro, V
    Siguero, M.
    Zeaiter, A.
    Longo, F.
    Zaman, K.
    Anton, A.
    Paredes, A.
    Huidobro, G.
    Subbiah, V
    ESMO OPEN, 2022, 7 (05)
  • [44] A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
    Litton, Jennifer Keating
    Blum, Joanne Lorraine
    Im, Young-Hyuck
    Martin, Miguel
    Mina, Lida A.
    Roche, Henri Hubert
    Rugo, Hope S.
    Visco, Fran
    Zhang, Charlie
    Lokker, Nathalie Andrienne
    Lounsbury, Debra L.
    Eiermann, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [45] Phase 2 trial with safety-run in of gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive HER2 negative breast cancer
    Phadke, Sneha
    Yu, Menggang
    Miller, Kathy
    Shah, Ami
    Danciu, Oana
    Wisinski, Kari
    CANCER RESEARCH, 2020, 80 (04)
  • [46] Serial circulating tumor DNA samples from patients with metastatic breast cancer and BRCA1/2 mutations.
    Collier, Katharine
    Tallman, David
    Weber, Zachary
    Haynam, Marcy
    Adams, Elizabeth J.
    Jenison, Janet
    Asad, Sarah
    Lustberg, Maryam B.
    Cherian, Mathew Amprayil
    Ramaswamy, Bhuvaneswari
    Sardesai, Sagar D.
    Williams, Nicole Olivia
    Wesolowski, Robert
    VanDeusen, Jeffrey Bryan
    Gatti-Mays, Margaret Elena
    Pariser, Ashley
    Mortazavi, Amir
    Stover, Daniel G.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [47] Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes
    Walsh, Elaine M.
    Mangini, Neha
    Fetting, John
    Armstrong, Deborah
    Chan, Isaac S.
    Connolly, Roisin M.
    Fiallos, Katie
    Lehman, Jennifer
    Nunes, Raquel
    Petry, Dana
    Reynolds, Jeffrey
    Shah, Mirat
    Smith, Karen L.
    Visvanathan, Kala
    Lauring, Josh
    Park, Ben H.
    Stearns, Vered
    Wolff, Antonio C.
    CLINICAL BREAST CANCER, 2022, 22 (04) : 319 - 325
  • [48] PYTHIA: A phase II study of palbociclib plus fulvestrant for pretreated patients with ER+/HER2-metastatic breast cancer
    Zardavas, D.
    Regan, M.
    Maibach, R.
    Ruepp, B.
    Hiltbrunner, A.
    Blacher, L.
    Gelber, R.
    Gebhart, G.
    Di Leo, A.
    Hilbers, F.
    Colleoni, M.
    Zoppoli, G.
    Bertelli, G.
    Bliss, J.
    Duhoux, F.
    Piccart, M.
    Malorni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2-metastatic breast cancer treated with CDK4/6 inhibitors
    Antras, Jesus Fuentes
    El Ghamrasni, Samah
    Zou, Jinfeng
    Dou, Aaron
    Elliott, Mitchell J.
    Avery, Lisa
    Bratman, Scott Victor
    Cescon, David W.
    Bedard, Philippe L.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
    Toms, C.
    Chopra, N.
    Houlton, L.
    Jarman, K.
    Kilburn, L.
    Bliss, J.
    Turner, N.
    ANNALS OF ONCOLOGY, 2016, 27
12345